

Per saperne di più

1. **Wells G**, Tugwell P, Shea B, Guyatt G, Peterson J, Zytaruk N, Robinson V, Henry D, O'Connell D, Cranney A; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. *Endocrine Rev* 2002;23:529-539.
2. **Rossouw JE**, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. *JAMA* 2002, 288: 321- 333.
3. **Lindsay R**, Gallagher JC, Kleerekoper M, Pickar JH. Effect of Lower Doses of Conjugated Equine Estrogens With and Without Medroxyprogesterone Acetate on Bone in Early Postmenopausal Women. *JAMA* 2002; 287:2668-2676.
4. **Weiss SR**, Ellman H, Dolker M. A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss. Transdermal Estradiol Investigator Group. *Obstet Gynecol* 1999; 94:330-336.
5. **van de Weijer PHM**, Mattsson LA, Ylikorkala O. Benefits and risks of long-term low-dose oral continuous combined hormone therapy. *Maturitas* 2007; 56 231-248.
6. **Gallagher JC**, Baylink DJ, Freeman R, McClung M. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. *J Clin Endocrinol Metab*, 2001; 86: 4717-4726.
7. **Cummings SR**, Ettinger B, Delmas PD, et al.; LIFT Trial Investigators. The effects of tibolone in older postmenopausal women. *N Engl J Med* 2008; 359: 697-708.

8. **Nelson ER**, Wardell SE, McDonnell DP. The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: Implications for the treatment and prevention of osteoporosis. *Bone* 2013; 53: 42–50.
9. **Delmas PD**, Bjarnason NH, Mitlak BH et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. *N Engl J Med*. 1997;337:1641-1647.
10. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. *JAMA*, 1999;282:637-645.
11. **Jolly EE**, Bjarnason NH, Neven P, et al. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. *Menopause*, 2003;10(4): 337-344.
12. **Biskobing DM**. Update on bazedoxifene: a novel selective estrogen receptor modulator. *Clinical Interventions in Aging* 2007;2(3): 299-303.
13. **Miller PD**, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. *J Bone Miner Res* 2008; 23(4):525–535.
14. **Silverman SL**, Christiansen C, Genant HK, et al .Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. *J Bone Miner Res* 2008; 23(12): 1923-1934.
15. **Lindsay R**, Gallagher JC, Kagan R, Pickar JH, Constantine G. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women *Fertil Steril* 2009;92(3):1045-1052.